DHRHealth Institute for Research and Development
News & ViewsNewslettersContactBecome a Research Patient
DHRHealth Institute for Research and Development

Clinical Trial

A Randomized Phase Iii Study Of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax And Obinutuzumab In Untreated Older Patients (≥ 65 Years Of Age) With Chronic Lymphocytic Leukemia (Cll)

Study Status:

Open For Enrollment

Please contact us for more information or to learn if you are eligible to participate.

Study Purpose:

The primary objective of this study is to compare the progression-free survival (PFS) between control treatment and experimental treatment strategies: ibrutinib/obinutuzumab (IO) with ibrutinib maintenance (IM) versus ibrutinib/venetoclax/obinutuzumab (IVO) regardless of IM or observation.


Principal Investigator
Jose Cruz, MD
National Cancer Institute (NCI)
Type of Trial
© 2023 DHR Health Institute for Research & Development | All Rights Reserved | Terms & Conditions | Site By: KangoMedia
chevron-down linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram